Condition: Aortic Valve Stenosis · Sponsor: National and Kapodistrian University of Athens
This is a prospective, multicentre, investigator-initiated, randomized clinical trial clinical trial investigating the impact of beta-blockers administration among patients undergoing TAVI for severe aortic valve stenosis. Adults already receiving beta-blockers be assigned randomly in 1:1 ratio to either continue or withdraw the beta-blockers medication at least 72 hours before and at least 7 days after TAVI. The primary endpoint is permanent pacemaker implantation rates in 7 days after the procedure. Secondary endpoints include death, cardiogenic shock and arrhythmias/conduction abmormalities with time frame 12 months.
This description comes directly from the study's public registry record.
Leonidas Koliastasis, MD, MSc, PhD · 6974270752 · lkoliastasis@gmail.com
Odysseas Katsaros, MD · +306944362412 · odykatsaros@gmail.com
Always discuss trial participation with your own doctor first.
| Nicosia General Hospital | Nicosia, Cyprus | Recruiting |
| First Department of Cardiology, National and Kapodistrian University of Athens | Athens, Attica, Greece | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05721170